ADMA Biologics, Inc.
ADMA · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $426 | $258 | $154 | $81 |
| % Growth | 65.2% | 67.6% | 90.4% | – |
| Cost of Goods Sold | $207 | $169 | $119 | $80 |
| Gross Profit | $220 | $89 | $35 | $1 |
| % Margin | 51.5% | 34.4% | 22.9% | 1.4% |
| R&D Expenses | $2 | $3 | $4 | $4 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $74 | $59 | $52 | $43 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $5 | $5 | $19 | $13 |
| Operating Expenses | $81 | $67 | $75 | $60 |
| Operating Income | $139 | $22 | -$39 | -$58 |
| % Margin | 32.6% | 8.4% | -25.5% | -72.1% |
| Other Income/Exp. Net | -$13 | -$50 | -$27 | -$13 |
| Pre-Tax Income | $126 | -$28 | -$66 | -$72 |
| Tax Expense | -$72 | $0 | $0 | $0 |
| Net Income | $198 | -$28 | -$66 | -$72 |
| % Margin | 46.4% | -10.9% | -42.8% | -88.5% |
| EPS | 0.85 | -0.13 | -0.43 | -0.61 |
| % Growth | 753.8% | 69.8% | 29.5% | – |
| EPS Diluted | 0.81 | -0.13 | -0.43 | -0.61 |
| Weighted Avg Shares Out | 233 | 224 | 198 | 140 |
| Weighted Avg Shares Out Dil | 243 | 224 | 198 | 140 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $0 | $0 |
| Interest Expense | $14 | $25 | $19 | $13 |
| Depreciation & Amortization | $8 | $8 | $7 | $5 |
| EBITDA | $148 | $5 | -$40 | -$53 |
| % Margin | 34.6% | 2% | -25.6% | -65.6% |